Acknowledging biases improves geriatric care

Being aware of biases improves healthcare decisions, according to the Gerontological Society of America. A new report, “Recognizing Hidden Traps in Health Care Decision Making," provides guidelines to overcome barriers in providing care to elderly patients.

Intended for physicians, nurses, psychologists and many other medical professionals caring for the elderly, the report outlines common heuristics and cognitive biases as the barriers in proving effective care.

“Everyone involved in health care decision making—including patients, providers, and caregivers—benefits from being aware of these shortcuts. The heuristics and biases outlined in the report are very common—we all use them,” said Jake Harwood, PhD, chair of the advisory board that oversaw the new publication’s development. “Sometimes they are functional, but a lot of the time they lead to poor decision making. What's great about the report is that it raises awareness of these shortcuts, and awareness is a great way of improving decision making.”

The report goes through hypothetical cases in which nonprescription analgesics and recommended immunizations are used. When using nonprescription painkillers, patients must strictly follow the labels on medication or risk developing negative side effects. The factor is multiplied in geriatric patients. In each case, the report gives communication tips on how to avoid biases with the overall hope that the report will improve the decision-making process.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.